The purpose of this trial is to allow patients to continue on HOE 901 until launch and to gather additional long-term safety data.

Inclusion Criteria:

• Subjects treated with HOE901 and who, in the judgement of the investigator, have benefited from the use of HOE 901 in a previous clinical study with HOE 901.
• Subjects treated with HOE 901 in a previous clinical study with HOE 901 for whom a change of basal insulin would destabilise glucose metabolism.
• Subjects who are likely to comply with the investigator's instructions.

Exclusion Criteria:

• Evidence of an uncooperative attitude.
• Subject not on adequate contraception, or who is pregnant, or breast feeding.
• Subject unable to understand informed consent.
• Patient receiving or likely to receive HOE901 treatment outside of SPC or PI recommendations.
• Subject becomes pregnant or is planning to become pregnant.